<DOC>
	<DOC>NCT01789788</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6811135 in patients with type 2 diabetes mellitus. Patients will be randomized to receive either RO6811135 or placebo daily for 2 weeks, with a follow-up examination 2 to 3 weeks after the last dose of study drug.</brief_summary>
	<brief_title>A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Adult patients, 18 to 65 years of age, inclusive Type 2 diabetes mellitus according to WHO criteria diagnosed for at least 3 months prior to screening On stable dose of metformin for at least 2 months prior to screening Fasting plasma glucose during the screening period &lt;/= 240 mg/dL Hemoglobin A1c (HbA1c) levels at screening &gt;/= 6.5% and &lt;/= 10.5% Evidence of insulin secretory capacity at screening Body mass index (BMI) 27 to 42 kg/m2, inclusive Females of childbearing potential and males with female partners of childbearing potential must agree to use effective contraception as defined by protocol Type 1 diabetes Acquired or secondary forms of diabetes such as those resulting from pancreatic surgery/injury, cystic fibrosis related diabetes History of acute metabolic complications such as diabetic ketoacidosis or state of hyperosmolar hyperglycemia Evidence or history of clinically significant diabetic complications such as clinically severe diabetic peripheral neuropathy, clinically significant nephropathy as judged by the investigator, or preproliferative/proliferative diabetic retinopathy as judged by the investigator History of severe symptomatic hypoglycemia (requiring assistances of a third party) within 6 months prior to screening History or presence of clinically significant concomitant disease or disorder Hemoglobin level below the lower limit of reference range at screening Pregnant or lactating women History of anaphylaxis or severe systemic hypersensitivity or allergic reactions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>